HCM · LONDON STOCK EXCHANGE ·
HUTCHMED China Ltd
US FDA Grants Sovleplenib Orphan Drug Designation
Our AI’s take
The announcement confirms that HUTCHMED’s lead candidate sovleplenib received US FDA Orphan Drug Designation for primary immune thrombocytopenia (ITP).
The full digestion is for members. What is good, what is bad and why, the numbers that matter, and the chart, then ask about it by voice or text.
Join freeNew to announcements? Learn what an RNS is and why prices move.